Biocon is gearing up to become a dominant player in the diabetes and obesity drug market. This comes as the pharma world ...

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.

Doctors have warned users of medicines such as Ozempic Wegovy and Mounjaro about an irreversible potential side effect ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

The overturning of the FDA’s lab-developed tests rule is just the tip of the iceberg. With the loss of Chevron deference, ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Stocks were boosted in May by easing trade tensions, solid corporate earnings and signs the U.S. economy remains resilient ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

Novo Nordisk (NYSE: NVO) and Cava Group (NYSE: CAVA) are excellent choices. Novo Nordisk's shares have significantly lagged ...